Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
iShares Trust iShares Russell 2000 BuyWrite ETF
(NY:
IWMW
)
41.52
+0.45 (+1.10%)
Official Closing Price
Updated: 8:00 PM EDT, Oct 24, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about iShares Trust iShares Russell 2000 BuyWrite ETF
< Previous
1
2
3
Next >
Bloom Energy Stock Jumped 7% This Morning – Here’s What Happened
September 16, 2025
Via
Stocktwits
Why Is aTyr Stock Falling Today?
September 15, 2025
Via
Stocktwits
IonQ Stock Stokes Retail Optimism After Receiving Necessary Clearances For Oxford Ionics Acquisition: Retail Sees ‘Multitrillion Dollar Market Company’
September 15, 2025
Via
Stocktwits
Sellas Life Sciences Stock In Spotlight After Institutional Investor Exercises Existing Warrants
September 11, 2025
In consideration for the immediate exercise of the warrants in full, the institutional investor will receive new, unregistered warrants in a private placement to purchase up to 19.69 million shares of...
Via
Stocktwits
Wolfpack Research Reveals Short Position In EV Maker Faraday Future
September 11, 2025
Via
Stocktwits
Maze Therapeutics Stock Just Shot Up 24% Pre-Market Today – Here’s What Happened
September 11, 2025
Via
Stocktwits
Soleno Therapeutics Stock Tanks After Patient Treated With Drug Dies – More Details Inside
September 10, 2025
Soleno said that its assessment of the death is the same as the treating physician, who said that the death is not related to the treatment with Vykat XR.
Via
Stocktwits
Topics
Death
Rapport Therapeutics Stock Rockets 204% Pre-Market To Head Toward All-Time Highs – Here’s What Happened
September 08, 2025
Via
Stocktwits
Immunome Stock Rises After Craig-Hellum Initiates Coverage With $26 Price Target: Here’s Why The Analyst Sees An ‘Attractive Entry Point’
September 05, 2025
Via
Stocktwits
Novavax COVID-19 Vaccine Approved In Japan, Triggers Milestone Payment From Partner Takeda
September 04, 2025
Via
Stocktwits
Hedge Fund Reportedly Prepares To Launch Board Fight At OraSure Technologies: Retail Investors Believe It’s Good News
September 09, 2025
Altai Capital Management is one of the largest owners of OraSure and has increased its stake from 3% at the end of June to 5% in recent weeks, in an effort to press for board representation, Reuters...
Via
Stocktwits
Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More
September 04, 2025
While the FDA was originally expected to decide on the company’s application for Pyrukynd in treating thalassemia by September 7, its decision is now expected by December 7.
Via
Stocktwits
FDA Says No Advisory Committee Meeting Needed For Aquestive’s Oral Epinephrine Film
September 04, 2025
Via
Stocktwits
Wave Life Sciences Tumbled 19% Today, But Not Everyone’s Disappointed – Find Out Why
September 03, 2025
Via
Stocktwits
Tectonic Stock Soars Pre-market After Tuesday’s Sell-Off: Oppenheimer Is Hopeful About Company’s Lead Candidate
September 03, 2025
Via
Stocktwits
Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update
September 02, 2025
The company was testing the drug in an early-stage trial in patients with ovarian cancer and non-small cell lung cancer.
Via
Stocktwits
Dynavax’s Experimental Shingles Vaccine Shows Positive Results In Study: Retail Expects Stock Rally To Continue Into Friday
August 21, 2025
Via
Stocktwits
Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’
August 19, 2025
Via
Stocktwits
Vanda Pharma Stock Rockets 9% After Federal Appeals Court Sets Aside FDA Action: Retail Expects Stock To Cross $5-Mark
August 18, 2025
Via
Stocktwits
US FDA Withdraws Approval For Amylyx’s Neurodegenerative Disorder Drug, But BofA Hikes Price Target
August 28, 2025
Bank of America analyst Tim Anderson raised the firm's price target on Amylyx to $14 from $10 while keeping a ‘Buy’ rating on the shares after the company reiterated earlier this week that it has a...
Via
Stocktwits
PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided
August 19, 2025
Via
Stocktwits
This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’
August 18, 2025
Via
Stocktwits
Soleno Therapeutics Stock Slumps After Scorpion Capital Reveals Short Position: But Retail’s Not Pessimistic Yet
August 15, 2025
Via
Stocktwits
This Aviation Stock Has Doubled In 2025, Surged Over 200% In 12 Months, And Is Trending On Friday – Do You Own It?
August 15, 2025
Via
Stocktwits
Precigen Stock Shot Through The Roof On Friday Morning – Here’s Why
August 15, 2025
The company stated that Papzimeos is now the first and only FDA-approved therapy for the treatment of adults with recurrent respiratory papillomatosis.
Via
Stocktwits
Aquestive Therapeutics Stock Is Rising Pre-Market – Its $75M Funding Agreement Draws Divided Opinions From Retail
August 14, 2025
Via
Stocktwits
Schrödinger Discontinues Clinical Program After Two Patient Deaths
August 14, 2025
Via
Stocktwits
Novavax CFO Says Sanofi To Cover Majority Of Future Nuvaxovid Study Costs, Retail Urges Partnership Diversification
August 06, 2025
Via
Stocktwits
Hertz Expands Program Allowing Prolonged 3-Day Test Drives Before Vehicle Purchase To Over 100 Cities
August 14, 2025
Consumers can test the vehicles for up to three days before purchasing at a low daily rate.
Via
Stocktwits
Ardelyx Stock Soars On Price Target Hikes After Upbeat Q2 Report: Retail Sees More Revisions Coming
August 05, 2025
Via
Stocktwits
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.